Auxilium Pharmaceuticals, Inc. (NASDAQ:AUXL)

CAPS Rating: 3 out of 5

A specialty biopharmaceutical company with a focus on developing and marketing products to urologists, endocrinologists, orthopedists and select primary care physicians.

Results 1 - 13 of 13

Recs

0
Member Avatar lnlrmtg (< 20) Submitted: 1/8/2014 2:31:12 AM : Outperform Start Price: $20.76 AUXL Score: -15.61

fundamentals

Recs

0
Member Avatar RumbachStock (36.47) Submitted: 6/18/2013 3:38:42 PM : Outperform Start Price: $17.24 AUXL Score: -8.28

Net working capital of $453M and average cash flow. Perhaps not a bargain, but it definitely seems cheap.

Recs

0
Member Avatar 21popsontop (< 20) Submitted: 11/24/2010 5:39:07 AM : Outperform Start Price: $19.70 AUXL Score: -68.99

Drug dealers with a license.

Recs

0
Member Avatar Ikeydoc (< 20) Submitted: 7/4/2009 11:40:46 AM : Outperform Start Price: $29.95 AUXL Score: -160.19

Release of treatment for Dupuytrens Disease

Recs

0
Member Avatar greenwave3 (53.04) Submitted: 8/27/2008 12:18:19 AM : Underperform Start Price: $39.79 AUXL Score: +112.34

Nice products, too much hype. How can you justify a market cap of $1.6 Billion with sales of under $100 Million? Some claim 20% annual sales growth. Even assuming they're correct, this one needs to be chopped in half before we even start to think about a fair valuation.

Recs

0
Member Avatar bernies1 (< 20) Submitted: 3/24/2008 8:18:56 PM : Outperform Start Price: $26.47 AUXL Score: -80.08

good stock

Recs

0
Member Avatar supez2004 (27.53) Submitted: 3/3/2008 1:08:22 AM : Outperform Start Price: $32.04 AUXL Score: -95.44

Xiaflex has potential to be a blockbuster drug in a niche market without many competitors ...

Recs

0
Member Avatar datasource (< 20) Submitted: 2/25/2008 4:06:07 PM : Underperform Start Price: $33.22 AUXL Score: +93.48

Overepriced with negative earnings for the foreseable future.

Also is currently a one-product company with mixed results in the whole synthetic testosterone marketplace. There are negative stories in the print press regarding the effectiveness of such products, including at least one that suggests that treatments can have the opposite of the desired effect.

Recs

0
Member Avatar NVR2LATE4MONEY (< 20) Submitted: 12/6/2007 4:02:19 PM : Outperform Start Price: $28.25 AUXL Score: -69.34

Auxl has a hot pipeline

Recs

0
Member Avatar htbrennan (51.22) Submitted: 8/9/2007 12:03:28 PM : Outperform Start Price: $22.53 AUXL Score: -56.10

CEO is a marketer,Exec. VP, Medimmune, rather than a Doc. Already have product and in late stage with new, so marketing is important.

Recs

2
Member Avatar mblin13 (63.44) Submitted: 3/1/2007 12:57:53 PM : Outperform Start Price: $12.32 AUXL Score: +6.41

downside provided by testim;
other drugs in phase 3 trials;
stock could triple

Recs

0
Member Avatar hlacheen (99.01) Submitted: 2/14/2007 12:32:08 AM : Underperform Start Price: $14.54 AUXL Score: +13.28

Another crappy pharmaceutical company that will never earn a profit.

Recs

1
Member Avatar martinlemalin (< 20) Submitted: 1/20/2007 4:34:19 PM : Outperform Start Price: $14.20 AUXL Score: -11.88

.. the way I see it it's more or less a casino play ..

Results 1 - 13 of 13

Featured Broker Partners


Advertisement